- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: Neonatal jaundice.
Displaying page 1 of 1.
EudraCT Number: 2011-004417-16 | Sponsor Protocol Number: 5022LC | Start Date*: Information not available in EudraCT |
Sponsor Name:St. Elisabeth Hospital | ||
Full Title: CEFTRIAXONE NEONATAL THERAPY: A RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE EFFECT OF CEFTRIAXONE ON HYPERBILIRUBINEMIA | ||
Medical condition: Hyperbilirubinemia | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-017434-45 | Sponsor Protocol Number: 64,185-202 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:InfaCare Pharmaceutical Corporation | |||||||||||||
Full Title: A Phase 2b, Multicenter, Single-dose, Blinded, Randomized, Placebo-controlled, Dose-escalation, Safety and Efficacy Trial of Stannsoporfin in Neonates with Hyperbilirubinemia | |||||||||||||
Medical condition: Neonatal hyperbilirubinemia Hiperbilirubinemia neonatal | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002148-15 | Sponsor Protocol Number: 201500214815 | Start Date*: 2017-06-01 |
Sponsor Name:Bethesda Diabetes research Center (BDRC) | ||
Full Title: Pregnancy Outcomes: Effects of Metformin Study (POEM Study) a long term randomized controlled parallel group study in gestational diabetes mellitus | ||
Medical condition: Gestational diabetes mellitus | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-004958-42 | Sponsor Protocol Number: MOM-M281-003 | Start Date*: 2019-01-11 | |||||||||||
Sponsor Name:Momenta Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease ... | |||||||||||||
Medical condition: Early onset Severe Hemolytic Disease of the fetus and newborn (HDFN) | |||||||||||||
|
|||||||||||||
Population Age: In utero, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) SE (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000043-74 | Sponsor Protocol Number: PNAS0122 | Start Date*: 2023-07-27 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Defining and predicting neonatal inadaptation after gestational exposure to antidepressants: longitudinal exploratory analysis of psychoneuroendocrine risk factors and complications | ||
Medical condition: major depressive disorder poor neonatal adaptation syndrome (after antidepressant use during pregnancy) | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002622-79 | Sponsor Protocol Number: IMIB-GU-2019-02 | Start Date*: 2020-06-17 |
Sponsor Name:Fundación para la Formación e Investigación Sanitarias de la Región de Murcia | ||
Full Title: Gestational treatment with Ursodeoxycholic Acid compared to Placebo to Reduce Severity of Gestational Diabetes Mellitus diagnosed at 24-28 weeks’ gestation | ||
Medical condition: Gestational Diabetes Mellitus | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004680-31 | Sponsor Protocol Number: 2018-004680-31 | Start Date*: 2019-08-16 | ||||||||||||||||
Sponsor Name:Lene Ringholm | ||||||||||||||||||
Full Title: A randomised controlled trial comparing the effect of the faster-acting insulin analog - insulin Fiasp® – versus insulin Novorapid® in the treatment of women with type 1 or type 2 diabetes during p... | ||||||||||||||||||
Medical condition: Type 1 and type 2 diabetes during pregnancy and lactation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001644-19 | Sponsor Protocol Number: NUIG-2016-01 | Start Date*: 2016-11-10 | |||||||||||
Sponsor Name:National University of ireland Galway | |||||||||||||
Full Title: A Randomised Placebo Controlled Trial of the effectiveness of Early MEtformin in Addition to Usual Care in the Reduction of Gestational Diabetes Mellitus Effects (EMERGE) | |||||||||||||
Medical condition: Gestational Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002031-32 | Sponsor Protocol Number: PASS-2007 | Start Date*: 2008-05-05 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA S. GERARDO DI MONZA | |||||||||||||
Full Title: Phase III study protocol to compare conservative and active treatment during the third stage of labour in physiological childbirth | |||||||||||||
Medical condition: THIRD STAGE OF LABOR MANAGEMENT | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003207-19 | Sponsor Protocol Number: PLD11-01 | Start Date*: 2013-11-29 |
Sponsor Name:Radboud University Nijmegen Medical Center | ||
Full Title: An international, multicenter, randomized controlled clinical trial assessing the efficacy of Ursodeoxycholic acid as a volume reducing treatment for symptomatic polycystic livers | ||
Medical condition: Patients suffering from symptomatic polycystic liver disease (PLD) with underlying diagnosis of isolated polycystic liver disease (PCLD) or autosomal dominant kidney disease (ADPKD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002880-82 | Sponsor Protocol Number: GUARD | Start Date*: 2020-05-05 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: Randomised controlled trial of Gestational treatment with Ursodeoxycholic Acid compared to Metformin to Reduce effects of Diabetes mellitus | |||||||||||||
Medical condition: Gestational Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000789-13 | Sponsor Protocol Number: Trial_version1 | Start Date*: 2013-07-05 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: Vitamin D And Lifestyle Intervention for Gestational Diabetes Mellitus (GDM) Prevention - A European multicentre, randomised trial: Vitamin D limb. | |||||||||||||
Medical condition: Gestational diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019252-41 | Sponsor Protocol Number: 242187 | Start Date*: 2011-08-03 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: DALI dosing study of Vitamin D in obese pregnant women | |||||||||||||
Medical condition: Gestational diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001631-39 | Sponsor Protocol Number: AT342-02 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Audentes Therapeutics Inc. | ||||||||||||||||||
Full Title: VALENS: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT342, an AAV8-Delivered Gene Tra... | ||||||||||||||||||
Medical condition: Crigler Najjar syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003832-54 | Sponsor Protocol Number: LUM001-303 | Start Date*: 2013-11-28 | |||||||||||
Sponsor Name:Mirum Pharmaceuticals, Inc. | |||||||||||||
Full Title: A MULTICENTRE EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND DURABILITY OF THE THERAPEUTIC EFFECT OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATME... | |||||||||||||
Medical condition: Alagille syndrome (ALGS). This is an example of cholestatic liver disease in children. In patients with Alagille syndrome, impairment of the egress of bile acids from the liver leads to cholestasis... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001045-14 | Sponsor Protocol Number: SAF001 | Start Date*: 2013-04-22 | |||||||||||
Sponsor Name:Promethera Biosciences | |||||||||||||
Full Title: SAF 001: A long-term safety follow-up study of patients suffering from Urea Cycle disorders (UCD) or Crigler-Najjar Syndrome (CN) having received infusions of HepaStem. | |||||||||||||
Medical condition: Crigler-Najjar syndrome is associated with a complete or partial hepatic deficit of bilirubin glucuronosyltransferase activity and is apparent during the neonatal period by intense jaundice. The ur... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) PT (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001211-22 | Sponsor Protocol Number: MRX-502 | Start Date*: 2019-10-29 | |||||||||||
Sponsor Name:Mirum Pharmaceuticals Inc. | |||||||||||||
Full Title: MRX-502: Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis ... | |||||||||||||
Medical condition: Progressive Familial Intrahepatic Cholestasis (PFIC) In patients with progressive familial intrahepatic cholestasis (PFIC), impairment of the egress of bile acids from the liver leads to cholestasi... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) HU (Completed) PL (Completed) AT (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003395-39 | Sponsor Protocol Number: MRX-503 | Start Date*: 2020-02-14 | |||||||||||
Sponsor Name:Mirum Pharmaceuticals Inc. | |||||||||||||
Full Title: MRX-503: An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Maralixibat in the Treatment of Subjects with Progressive Familial Intrahepatic Cholestasis (PFIC) | |||||||||||||
Medical condition: In patients with progressive familial intrahepatic cholestasis (PFIC), impairment of the egress of bile acids from the liver leads to cholestasis, hepatocellular injury and damage, and progressive ... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) PL (Completed) FR (Completed) HU (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002120-33 | Sponsor Protocol Number: HLSCS01-11 | Start Date*: 2013-12-06 | ||||||||||||||||||||||||||
Sponsor Name:AZIENDA SANITARIA OSPEDALIERA O.I.R.M. - S. ANNA | ||||||||||||||||||||||||||||
Full Title: Human Liver Stem Cells (HLSCs) in patients suffering from liver-based inborn metabolic diseases causing life-threatening neonatal onset of hyperammonemic encephalopathy | ||||||||||||||||||||||||||||
Medical condition: neonatal hyperammonemic encephalopathy associated with inborn liver metabolic diseases | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004074-28 | Sponsor Protocol Number: UKHEP001 | Start Date*: 2012-07-20 | |||||||||||
Sponsor Name:Promethera Biosciences | |||||||||||||
Full Title: A prospective, open label, multicenter, randomized, safety and preliminary efficacy study of one cycle of Promethera HepaStem® in Urea Cycle Disorders and Crigler-Najjar Syndrome patients | |||||||||||||
Medical condition: Crigler-Najjar syndrome is associated with a complete or partial hepatic deficit of bilirubin glucuronosyltransferase activity and is apparent during the neonatal period by intense jaundice. The ur... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
